Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy

Dermatologic Surgery

Volumn 27, Issue 6, 2001, Pages 561-564

  Smith, Kathleen J ^a,c   Germain, Margeruite ^b   Skelton, Henry ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; CYTOKINE; FLUOROURACIL; IMIQUIMOD;

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; BOWEN DISEASE; CANCER IMMUNOTHERAPY; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SIDE EFFECT; SQUAMOUS CELL CARCINOMA;

ADMINISTRATION, CUTANEOUS; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BOWEN'S DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEG; MALE; MIDDLE AGED; PILOT PROJECTS; SKIN NEOPLASMS; SURVIVORS; TREATMENT OUTCOME;

EID: 0034973036     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2001.00149.x     Document Type: Article

References (25)

1. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy
2. Neoplastic disorders and organ transplantation
3. Posttransplant lymphoproliferative disorder in pediatric renal transplantation
4. The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high: A clinical study to assess risk factors for keratotic skin lesions and skin cancer
5. Skin cancer in heart transplant recipients: Frequency and risk factor analysis
6. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463
7. Cytokine induction by the immunomodulators imiquimod and S-27609
8. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod
9. Interteukin 12: A proinflammatory cytokine with immunoregulatory functions
10. Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen specific T cells
11. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12
12. Chemokines and chemokines receptors in T-cell priming and Th1/Th2-mediated responses
13. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells
14. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells
15. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
16. Topical imiquimod immunotherapy inhibits tumor growth in a mouse model of infantile vascular tumors
17. Angiogenesis research. Cancer drugs found to work in new ways
18. In vivo gene therapy with interteukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model
19. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas
20. Bowen's disease and 5-fluorouracil
21. Bowen's diseasea retrospective review of clinical management
22. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19) F-magnetic resonance spectroscopy
23. New possibilities in chemotherapy for colorectal cancer
24. Where do we stand with 5-fluorouracil?
25. Th1/Th2 balance in cancer, transplantation and pregnancy